瑞迪博士实验室正在加强努力,为抗击新冠病毒病提供治疗和预防产品(药物和疫苗)。随着Redyx(瑞德西韦)的推出(Remdesivir) 和Avigan(法匹拉韦(Favipiravir)Dr.Reddy’s瑞迪博士重申了为新冠病毒病患者提供关键药物的承诺。
除了药物,瑞迪博士还于2021年5月1日收到了来自俄罗斯的15万剂卫星5(Sputnik V)疫苗,目前正在印度推广该疫苗。 公司预计在5月和6月将稳步提高产能,并计划在未来8-12个月内为全国1.25亿人接种疫苗。瑞迪博士还会与俄罗斯直接投资基金(RDIF)合作,在其他几个市场推出产品,特别是在新兴市场。
原料药和服务首席执行官迪帕克•萨普拉就卫星5疫苗的许可、软启动、在印度的生产、定价和卫星5轻型疫苗的未来道路与《今日印度》进行了谈话。
点击这里 查看迪帕克•萨普拉与《今日印度》的独家采访。
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.